Immuron posts AUD$7.7 million FY26 Travelan sales

• Immuron reported unaudited FY26 global Travelan sales of AUD$7.7 million, up 6% from the previous year.
• Immuron shares were unchanged at A$0.043 after the sales update.
• The company linked growth in Australia and the U.S. to digital marketing, retail expansion and increased travel.

Immuron (NASDAQ:IMRN) reported unaudited FY26 global Travelan sales of AUD$7.7 million, representing year-over-year growth of 6%.

Second-half sales increased 7% to AUD$3.5 million, while fourth-quarter sales rose 2% to AUD$2 million.

Australian sales grew 10% to AUD$5.8 million, while U.S. sales increased 7% to AUD$1.8 million, or 13% to USD$1.2 million.

Canadian sales fell 55% to AUD$0.2 million for FY26, although fourth-quarter sales increased 427% as promotions and brand-awareness programs expanded.

Immuron previously reported Q3 global sales of AUD$1.5 million, up 16%, with nine-month sales increasing 7% to AUD$5.7 million.

Travelan is listed as a medicine in Australia, licensed as a natural health product in Canada and sold as a dietary supplement in the U.S.